Polygon Health

11/04/2025

*Phase 1 Autologous CAR-T Clinical Trial Results: Hopeful Responses for Multiple Myeloma Patients*

Recent Phase 1 trials using autologous CAR-T therapies are delivering hope to patients battling tough cancers, especially multiple myeloma. Key Takeaways:

High response rates: Multiple myeloma patients in these trials are experiencing strong overall and complete responses, even if they’ve relapsed or run out of options with other treatments.

Advanced targeting: New bicistronic CAR-Ts are designed to target two antigens (CD19 and CD20), reducing the likelihood that cancer cells will escape detection and improving safety. This could mean more myeloma patients may have access to care in outpatient settings.

Expanded access: FDA-approved autologous CAR-Ts, like Yescarta, are now showing promising efficacy and safety whether patients are eligible for transplant or not, opening doors for more individuals with myeloma to try potentially curative therapy.

These findings highlight the crucial role clinical trials play for multiple myeloma patients—not only as access points for personalized, cutting-edge treatments, but also as opportunities to help advance breakthrough therapies for the entire myeloma community. Participating in trials helps bring hope and innovation closer to all those affected by this disease.

Interested to Learn More? Link in Comments.

Send a message to learn more

10/31/2025

VIRTUAL WALK/RUN | IN PERSON in HOUSTON - Sign Up to Join. Link in Comments

10/28/2025

CLINICAL TRIAL NEWS:
New Myeloma Drug Combo Gives Fresh Hope for Patients: FDA Approves Blenrep + Velcade + Dexamethasone After Prior Treatments

If your multiple myeloma has come back or stopped responding after at least two different treatments, there’s a new option: a combination of Blenrep (belantamab mafodotin), Velcade (bortezomib), and dexamethasone.

This newly approved drug combo was tested in a large clinical trial with real patients. Compared to one of the most common options, it cut the risk of death in half and more than tripled the time before the cancer grew again—often giving many extra months and even years of life.

WHY IT MATTERS?

This approval is for people running out of choices, showing research continues to create new lifelines.

Clinical trials like DREAMM-7—thanks to patients who volunteered—make new treatments like this available.

While side effects are still present (especially eye issues), doctors see this as a meaningful advance, with the treatment also available in local community centers for easier access.

BOTTOM LINE:
Progress like this only happens because myeloma fighters step up to join trials. Every advance offers real hope for more time and better options at every stage of the journey.

INTERESTED IN LEARNING MORE? Links in Comment Below

Send a message to learn more

10/23/2025

NEW EVENT:

Practical Insights in and Translational Aspects of Novel Immune Therapies in MM

👇 Here’s how you can benefit:

Learn about state-of-the‐art immune therapies and how they’re being translated into practice

Understand what’s next on the horizon for myeloma care

Prepare for informed conversations with your hematologist/oncologist

Connect virtually with leading experts and peers in the myeloma community

09/16/2025

Celebrating a milestone at the White House! 🇺🇸

Polygon Health was honored to be recognized alongside CMS and other innovators for our commitment to modernizing the nation’s digital health ecosystem.

Our mission is simple yet powerful:
✨ Connect patients
⚡ Find opportunities
💙 Improve outcomes

If you or someone you love is living with Multiple Myeloma, Bladder Cancer, or Myositis, you don’t have to face it alone.

🌐 Join our free Patient Connect Map today and connect with patients, caregivers, and resources that can make a difference.

🔗 www.polygonhealth.com/map

05/06/2025

We’re always looking for ways to support you on your health journey - and today, we’re excited to share something that could make a real difference.

We’ve partnered with Massive Bio to help connect cancer patients with clinical trials that match their unique needs. Whether you’ve just been diagnosed or are currently in treatment, Massive Bio offers free, personalized support - from trial matching to enrollment and beyond.

We know how overwhelming this process can be. But with the right guidance, you don’t have to navigate it alone.

If you or someone you love are facing cancer, we invite you to explore whether a clinical trial could be a helpful next step.

Learn more here: https://www.polygonhealth.com/map/multiple-myeloma/sign-up-for-clinical-trials

03/13/2025

Our map is now LIVE!!! Help us spread the word.

10/25/2024

What causes multiple myeloma?

Comment your thoughts below:

Multiple myeloma is a rare type of blood cancer that most people do not know the cause of. It's still widely unclear what the cause for multiple myeloma is, but there are a few ideas. These cells play a critical role in our immune system by producing antibodies that help fight infections. Every year...

10/02/2024

Two months ago, we launched Patient Connect, and we're thrilled to have welcomed over 1,000 users to the platform since then. We've received valuable feedback on how to make Patient Connect even better.

Learn more here:
https://www.polygonhealth.com/map

09/10/2024

Patti Scialfa, Bruce Springsteen's wife, bravely shares her 6-year journey with . Let's shine a light on this rare blood cancer:

Multiple Myeloma Facts
• Affects plasma cells in bone marrow
• Estimated 35,000 new cases in 2024
• More common in people over 45
• Twice as common in Black individuals
• Symptoms can include fatigue, bone pain, and easy bruising

Our Multiple Myeloma map connects people who are on similar health journeys and provides helpful resources based on their personal stories.

Join today at www.polygonhealth.com/map

Together, we can make sure no one has to fight multiple myeloma alone!

09/04/2024

September is

Did you know that…

accounts for approximately 1.8% of all cancers diagnosed in the United States. (American Cancer Society)

In 2024, it is estimated that around 35,000 new cases of multiple myeloma will be diagnosed in the U.S. (American Cancer Society)

About 95% of multiple myeloma cases occur in individuals aged 45 and older, with the median age at diagnosis being 69. (American Cancer Society)

Men are about 1.3 times more likely to develop multiple myeloma compared to women. (National Cancer Institute)

African Americans are approximately twice as likely to develop multiple myeloma compared to Caucasians. (American Cancer Society)

And rates have more than doubled over the past two decades due to new treatment options. (American Cancer Society)